Hormone-control regions mediate steroid receptor–dependent genome organization
Author
Publication date
2019ISSN
1088-9051
Abstract
In breast cancer cells, some topologically associating domains (TADs) behave as hormonal gene regulation units, within which gene transcription is coordinately regulated in response to steroid hormones. Here we further describe that responsive TADs contain 20- to 100-kb-long clusters of intermingled estrogen receptor (ESR1) and progesterone receptor (PGR) binding sites, hereafter called hormone-control regions (HCRs). In T47D cells, we identified more than 200 HCRs, which are frequently bound by unliganded ESR1 and PGR. These HCRs establish steady long-distance inter-TAD interactions between them and organize characteristic looping structures with promoters in their TADs even in the absence of hormones in ESR1+-PGR+ cells. This organization is dependent on the expression of the receptors and is further dynamically modulated in response to steroid hormones. HCRs function as platforms that integrate different signals, resulting in some cases in opposite transcriptional responses to estrogens or progestins. Altogether, these results suggest that steroid hormone receptors act not only as hormone-regulated sequence-specific transcription factors but also as local and global genome organizers.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
61 - Medical sciences
616 - Pathology. Clinical medicine
Keywords
Pages
12
Publisher
Cold Spring Harbor Laboratory Press
Collection
29;
Is part of
Genome Research
Recommended citation
Le Dily, François; Vidal, Enrique; Cuartero, Yasmina [et al.]. Hormone-control regions mediate steroid receptor-dependent genome organization. Genome Research, 2018, 29, p. 29-39. Disponible en: <https://genome.cshlp.org/content/29/1/29>. Fecha de acceso: 13 dic. 2021.
Grant agreement number
info:eu-repo/grantAgreement/EC/FP7/609989
info:eu-repo/grantAgreement/ES/MINECO/SAF2016-75006-P
Note
We thank the CRG Ultra-sequencing Facility for technical support and all members of the Chromatin and Gene Expression group for helpful discussions. We acknowledge the members of the 4DGenome project (CRG and CNAG-CRG, Barcelona), notably Thomas Graf, Marc A. Marti-Renom, and Guillaume Filion, as well as Ramon Amat (UPF, Barcelona) for their helpful comments on the manuscript. We thank Dr. Cheng-Ming Chiang (UT Southwestern Medical Center) for kindly providing antibody against BRD4. We received funding from the European Research Council under the European Union’s Seventh Framework Program (FP7/2007–2013)/ERC Synergy grant agreement 609989 (4DGenome). The content of this manuscript reflects only the author’s views and the Union is not liable for any use that may be made of the information contained therein. We acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’ and Plan Nacional (SAF2016-75006-P), as well as support of the CERCA Programme/Generalitat de Catalunya.
This item appears in the following Collection(s)
- Ciències de la Salut [973]
Rights
© 2019 Le Dily et al.; Published by Cold Spring Harbor Laboratory Press This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/


